<DOC>
	<DOC>NCT00434447</DOC>
	<brief_summary>This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events (SREs) beyond 12 months treatment</brief_summary>
	<brief_title>Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criteria: Documented bone metastases from breast cancer, prostate cancer or multiple myeloma Prior treatment with zoledronic acid for 12 yrs Life expectancy of at least 6 months Exclusion criteria: Prior treatment with bisphosphonates other than zoledronic acid Abnormal kidney function Current or previous dental problems or planned dental surgery Pregnant or likely to become pregnant during the study Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Bone metastases</keyword>
	<keyword>Skeletal Related Events (SREs)</keyword>
	<keyword>Renal Impairment</keyword>
	<keyword>Osteonecrosis of the Jaw (ONJ)</keyword>
	<keyword>Bone involvement</keyword>
	<keyword>Multiple Myeloma (MM)</keyword>
</DOC>